Dzmitry Dzemidovich
BridgeBio Oncology Therapeutics, which was spun out of BridgeBio Pharma (NASDAQ:BBIO) last year, has agreed to merge with Helix Acquisition Corp. II (NASDAQ:HLXB), a Boston-headquartered SPAC, to become a publicly traded biotech, the companies announced Friday.
The combined company, named BridgeBio